Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification.


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
04 2020
Historique:
received: 28 01 2020
pubmed: 29 2 2020
medline: 23 1 2021
entrez: 29 2 2020
Statut: ppublish

Résumé

Anal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50% 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and therapeutic options are needed. High-throughput proteomics and whole-exome sequencing were performed in 46 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used to establish groups

Identifiants

pubmed: 32107283
pii: S1535-9476(20)35025-8
doi: 10.1074/mcp.RA120.001954
pmc: PMC7124473
pii:
doi:

Substances chimiques

Neoplasm Proteins 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

690-700

Subventions

Organisme : NIMHD NIH HHS
ID : R01 MD007783
Pays : United States

Informations de copyright

© 2020 Trilla-Fuertes et al.

Références

CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Biotechnol. 2013 May;31(5):419-25
pubmed: 23455439
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Proteomics Clin Appl. 2013 Apr;7(3-4):283-91
pubmed: 23436753
J Cancer. 2019 Jan 29;10(4):874-884
pubmed: 30854093
Nat Methods. 2018 Jun;15(6):440-448
pubmed: 29735998
Oncotarget. 2017 Dec 8;9(1):464-476
pubmed: 29416628
Sci Rep. 2017 Aug 30;7(1):10100
pubmed: 28855612
Cancer Manag Res. 2018 Oct 25;10:4969-4980
pubmed: 30464597
Ann Oncol. 2016 Jul;27(7):1336-41
pubmed: 27052656
Oncotarget. 2018 Jan 8;9(11):9645-9660
pubmed: 29515760
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Expert Rev Mol Diagn. 2015 Jun;15(6):749-60
pubmed: 25959410
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Protoc. 2011 Aug 04;6(9):1290-307
pubmed: 21886097
Br J Cancer. 2018 Jan;118(1):106-116
pubmed: 29206819
Cancer Res. 2015 Jun 1;75(11):2243-53
pubmed: 25883093
Cancer Res. 2017 Oct 15;77(20):5445-5451
pubmed: 28807941
J Pathol. 2017 Mar;241(4):522-533
pubmed: 27976366
Nucleic Acids Res. 2015 Jan;43(Database issue):D662-9
pubmed: 25352552
Nature. 2009 Sep 10;461(7261):272-6
pubmed: 19684571
Cell Immunol. 2015 Jun;295(2):77-82
pubmed: 25863743
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Gastroenterology. 2005 Jan;128(1):51-62
pubmed: 15633123
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Methods Enzymol. 2008;439:111-29
pubmed: 18374160
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Br J Cancer. 2016 Jun 14;114(12):1387-94
pubmed: 27219019
J Mol Histol. 2018 Aug;49(4):389-398
pubmed: 29846864
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Oncogene. 2013 Oct 17;32(42):5026-37
pubmed: 23160375
Cancer Lett. 2015 Jan 28;356(2 Pt B):556-60
pubmed: 25305455
Lancet Oncol. 2017 Apr;18(4):446-453
pubmed: 28223062
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Ann Oncol. 2017 May 1;28(5):1036-1041
pubmed: 28453692
PLoS Comput Biol. 2009 Aug;5(8):e1000489
pubmed: 19714220
Mol Cancer Res. 2017 Nov;15(11):1542-1550
pubmed: 28784613
Comput Biol Chem. 2015 Dec;59 Pt B:98-112
pubmed: 26381164
Oncogene. 2013 Jun 6;32(23):2858-72
pubmed: 22797061
Sci Rep. 2017 May 24;7(1):2323
pubmed: 28539603
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
pubmed: 11309499
J Natl Compr Canc Netw. 2018 Jul;16(7):852-871
pubmed: 30006428
Oncogene. 2018 Oct;37(40):5416-5434
pubmed: 29867202
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Nat Biotechnol. 2010 Mar;28(3):245-8
pubmed: 20212490
J Exp Clin Cancer Res. 2019 Feb 18;38(1):84
pubmed: 30777099
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020

Auteurs

Lucía Trilla-Fuertes (L)

Biomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain.

Ismael Ghanem (I)

Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.

Angelo Gámez-Pozo (A)

Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Joan Maurel (J)

Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.

Laura G-Pastrián (L)

Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Marta Mendiola (M)

Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain.

Cristina Peña (C)

Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.

Rocío López-Vacas (R)

Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Guillermo Prado-Vázquez (G)

Biomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain.

Elena López-Camacho (E)

Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Andrea Zapater-Moros (A)

Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Victoria Heredia (V)

Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain; Translational Oncology Lab, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

Miriam Cuatrecasas (M)

Pathology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.

Pilar García-Alfonso (P)

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, /Dr. Esquerdo 46, 28007, Madrid, Spain.

Jaume Capdevila (J)

Medical Oncology Service, Vall Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Paseigg de la Vall d'Hebron 119, 08035, Barcelona, Spain.

Carles Conill (C)

Radiotherapy Oncology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.

Rocío García-Carbonero (R)

Medical Oncology Service, Hospital Universitario 12 de Ocubre, Av. de Córdoba s/n, 28041, Madrid, Spain.

Ricardo Ramos-Ruiz (R)

Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain.

Claudia Fortes (C)

Functional Genomics Center Zurich, University of Zurich/ETH Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.

Carlos Llorens (C)

Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain.

Paolo Nanni (P)

Functional Genomics Center Zurich, University of Zurich/ETH Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.

Juan Ángel Fresno Vara (JÁ)

Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain.

Jaime Feliu (J)

Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain; Cátedra UAM-Amgen, Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain. Electronic address: jaimefeliu@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH